Publications by authors named "Jane Perlmutter"

Claim this Profile
D
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
Mandeep Kaur, Katrina Dimitroff, Judy C Boughey, Laura J Esserman, Christina Yau, Jane Perlmutter

Ann Surg Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
Rita A Mukhtar, Katrina Dimitroff, Christina Yau, A Jo Chien, Eileen P Connolly, Jane Perlmutter

Ann Surg Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
Julie Van Hassel, Katrina Dimitroff, Christina Yau, Rita Mukhtar, Judy C Boughey, Jane Perlmutter

Ann Surg Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
Denise M Wolf, Christina Yau, Michael Campbell, Annuska Glas, Andrei Barcaru, Jane Perlmutter

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Ethan Basch, Deborah Schrag, Jennifer Jansen, Sydney Henson, Brenda Ginos, Jane Perlmutter

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.
Thomas U Marron, Jason J Luke, Brianna Hoffner, Jane Perlmutter, Connie Szczepanek

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace, Jane Perlmutter

Breast Cancer Res Treat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Jane Perlmutter

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Jane Perlmutter

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Michael J Campbell, Denise M Wolf, Christina Yau, Lamorna Brown-Swigart, Julie Wulfkuhle, Jane Perlmutter

Cell Rep Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Mark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, Lamorna Brown Swigart, Gillian L Hirst, Jane Perlmutter

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, Jane Perlmutter

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Rosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, Lamorna Brown-Swigart, Christina Yau, Jane Perlmutter

Cell Rep Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mepitel Film for the prevention of acute radiation dermatitis in breast cancer patients: a discussion of recent findings.
Molly A Chakraborty, Rosemary Hill, Kimberly Corbin, Jane Perlmutter, Jean L Wright

Ann Palliat Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials.
Shauna L Hillman, Aminah Jatoi, Carrie A Strand, Jane Perlmutter, Suzanne George

JAMA Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Mark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W Sayaman, Derrick Renner, Jane Perlmutter

Cancer Cell· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Mark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, A Jo Chien, Judy C Boughey, Jane Perlmutter

Breast Cancer Res Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilizing the clinical trial ecosystem to drive adoption of master protocols.
Abby Bronson, Marianne K Chase, Kimberly Fisher, Daniel Millar, Jane Perlmutter

Clin Trials· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, Jane Perlmutter

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
Jennifer Le-Rademacher, Supriya Mohile, Joseph Unger, Matthew F Hudson, Jared Foster, Jane Perlmutter

J Natl Cancer Inst Monogr· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
Naren Ramakrishna, Carey K Anders, Nancy U Lin, Aki Morikawa, Sarah Temin, Jane Perlmutter

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
Sharon H Giordano, Maria Alice B Franzoi, Sarah Temin, Carey K Anders, Sarat Chandarlapaty, Jane Perlmutter

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Jane Perlmutter

Cancer Cell· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
Ethan Basch, Deborah Schrag, Sydney Henson, Jennifer Jansen, Brenda Ginos, Jane Perlmutter

JAMA· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal I Lindeman, Kathleen Moore, Jane Perlmutter

J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis